Regeneron buys bankrupt 23andMe for $256m

The sale brings attention back to privacy concerns as Regeneron now controls genetic data from millions of 23andMe customers.

May 20, 2025 - 06:00

Regeneron buys bankrupt 23andMe for $256m

The sale brings attention back to privacy concerns as Regeneron now controls genetic data from millions of 23andMe customers.

Read the original article

Tags:

Previous Article

Power of collaboration more pertinent than ever says pharma experts

Apnimed to seek approval for sleep apnoea pill after Phase III success

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Tyra Biosciences’ TYRA-300 gains FDA rare paediatric disease status

Tyra Biosciences’ TYRA-300 gains FDA rare paediatric di...

Feb 2, 2024

Opinion: Want to end historic health care strikes? Fix a broken, outdated reimbursement model

Opinion: Want to end historic health care strikes? Fix ...

Oct 26, 2023

Biotech layoffs, slumping stocks, and a 2024 preview

Jan 18, 2024